|
Synonyms: BYM-338 | BYM338
Compound class:
Antibody
Comment: Bimagrumab is an investigational monoclonal antibody designed to treat the pathological muscle loss and weakness caused by the inflammatory muscle depleting disease, sporadic inclusion body myositis (sIBM).
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
| No information available. |
Summary of Clinical Use  |
| Bimagrumab is being assessed in Phase 2/III clinical trial as a treatment for sporadic inclusion body myositis [1] (NCT01925209) and in Phase 2 trials for sarcopenia (NCT02333331) or as an agent to reduce muscle wasting following hip fracture surgery (NCT02152761). |
| Mechanism Of Action and Pharmacodynamic Effects |
| Bimagrumab primarily targets the type II activin receptor ACVR2B [2], which is a type II receptor serine/threonine kinase. The antibody also has high affinity for ACVR2A, but this is much lower in comparison to ACVR2B binding. This action blocks myostatin-induced SMAD pathway signalling, which is hypothesised to improve the formation of skeletal muscle [3-4]. |
